Produktresumé, etikettering og indlægsseddel fremgår af bilag III for Efexor og tilknyttede navne (se bilag I).
the CHMP has recommended the amendment of the Marketing Authorisations for which the Summary of Product Characteristics, labelling and package leaflet are set out in Annex III for Efexor and associated names (see Annex I).